X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (35882) 35882
Newsletter (3846) 3846
Publication (2995) 2995
Book Review (559) 559
Book Chapter (272) 272
Newspaper Article (89) 89
Dissertation (76) 76
Magazine Article (76) 76
Conference Proceeding (65) 65
Book / eBook (33) 33
Trade Publication Article (22) 22
Reference (11) 11
Web Resource (8) 8
Data Set (4) 4
Transcript (4) 4
Paper (2) 2
Journal / eJournal (1) 1
Presentation (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (20139) 20139
index medicus (15158) 15158
male (14185) 14185
angiotensin (12450) 12450
animals (11969) 11969
hypertension (10201) 10201
female (9639) 9639
angiotensin-converting enzyme inhibitors - therapeutic use (6748) 6748
middle aged (6658) 6658
rats (6476) 6476
hypertension - drug therapy (5906) 5906
aged (5766) 5766
cardiac & cardiovascular systems (5042) 5042
peripheral vascular disease (4956) 4956
pharmacology & pharmacy (4704) 4704
research (4607) 4607
renin-angiotensin system (4575) 4575
blood pressure - drug effects (4350) 4350
angiotensin ii type 1 receptor blockers - therapeutic use (4210) 4210
antihypertensive agents - therapeutic use (4144) 4144
angiotensin ii (4046) 4046
blood-pressure (3981) 3981
heart failure (3747) 3747
adult (3746) 3746
angiotensin-ii (3711) 3711
risk factors (3679) 3679
blood pressure (3620) 3620
treatment outcome (3503) 3503
renin-angiotensin system - drug effects (3177) 3177
angiotensin ii type 1 receptor blockers - pharmacology (3151) 3151
mortality (3148) 3148
hypertension - physiopathology (2942) 2942
urology & nephrology (2813) 2813
drug therapy (2748) 2748
analysis (2708) 2708
drug therapy, combination (2684) 2684
diabetes (2682) 2682
oxidative stress (2589) 2589
mice (2549) 2549
enzymes (2463) 2463
physiology (2420) 2420
care and treatment (2398) 2398
ace inhibitors (2391) 2391
losartan (2363) 2363
angiotensin receptor antagonists (2290) 2290
medicine & public health (2222) 2222
angiotensin-converting enzyme inhibitors - pharmacology (2210) 2210
heart failure - drug therapy (2208) 2208
tetrazoles - therapeutic use (2187) 2187
expression (2163) 2163
rats, sprague-dawley (2156) 2156
angiotensin ii - pharmacology (2122) 2122
medicine, general & internal (2044) 2044
adrenergic beta-antagonists - therapeutic use (2030) 2030
health aspects (1996) 1996
renin-angiotensin system - physiology (1989) 1989
time factors (1920) 1920
valsartan (1910) 1910
tetrazoles - pharmacology (1886) 1886
physiological aspects (1879) 1879
cardiology (1815) 1815
heart-failure (1811) 1811
reports (1780) 1780
dose-response relationship, drug (1775) 1775
antihypertensive agents - pharmacology (1764) 1764
hypertension - complications (1760) 1760
disease models, animal (1731) 1731
internal medicine (1716) 1716
endocrinology & metabolism (1709) 1709
enzyme inhibitors (1672) 1672
renin (1665) 1665
aged, 80 and over (1648) 1648
losartan - pharmacology (1630) 1630
angiotensin receptor antagonists - therapeutic use (1615) 1615
medical research (1612) 1612
aldosterone (1607) 1607
myocardial-infarction (1606) 1606
cardiovascular (1585) 1585
risk (1573) 1573
prevention (1565) 1565
inflammation (1557) 1557
rats, wistar (1557) 1557
medicine (1546) 1546
angiotensin ii - metabolism (1531) 1531
disease (1528) 1528
calcium channel blockers - therapeutic use (1514) 1514
article (1479) 1479
angiotensin-converting enzyme inhibitors (1462) 1462
system (1442) 1442
heart (1440) 1440
abridged index medicus (1375) 1375
rodents (1367) 1367
fibrosis (1358) 1358
receptor, angiotensin, type 1 - metabolism (1355) 1355
medicine, experimental (1347) 1347
medicine, research & experimental (1342) 1342
therapy (1336) 1336
benzimidazoles - therapeutic use (1333) 1333
angiotensin-converting enzyme (1326) 1326
cardiovascular disease (1312) 1312
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (38623) 38623
Japanese (422) 422
German (253) 253
Russian (181) 181
Chinese (144) 144
French (114) 114
Spanish (108) 108
Korean (68) 68
Italian (54) 54
Hungarian (39) 39
Polish (31) 31
Portuguese (31) 31
Czech (26) 26
Danish (21) 21
Swedish (13) 13
Dutch (12) 12
Norwegian (11) 11
Turkish (10) 10
Ukrainian (8) 8
Finnish (5) 5
Slovak (5) 5
Hebrew (4) 4
Persian (4) 4
Serbian (4) 4
Croatian (3) 3
Lithuanian (3) 3
Romanian (2) 2
Bosnian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet, The, ISSN 0140-6736, 2011, Volume 377, Issue 9767, pp. 741 - 750
Summary Background Raised blood pressure is common in acute stroke, and is associated with an increased risk of poor outcomes. We aimed to examine whether... 
Internal Medicine | MEDICINE, GENERAL & INTERNAL | DESIGN | MANAGEMENT | ACUTE ISCHEMIC STROKE | INTRAVENOUS NIMODIPINE | GUIDELINES | CEREBRAL-HEMORRHAGE TRIAL | OUTCOMES | BLOOD-PRESSURE REDUCTION | HYPERTENSION | INTERVENTION | Meta-Analysis as Topic | Angiotensin II Type 1 Receptor Blockers - adverse effects | Humans | Middle Aged | Antihypertensive Agents - administration & dosage | Hypertension - drug therapy | Male | Stroke - physiopathology | Benzimidazoles - administration & dosage | Tetrazoles - administration & dosage | Treatment Failure | Aged, 80 and over | Female | Blood Pressure - drug effects | Benzimidazoles - adverse effects | Odds Ratio | Angiotensin II Type 1 Receptor Blockers - administration & dosage | Brain Ischemia - complications | Double-Blind Method | Drug Administration Schedule | Europe | Stroke - drug therapy | Hypertension - physiopathology | Antihypertensive Agents - adverse effects | Regression Analysis | Stroke - etiology | Aged | Tetrazoles - adverse effects | Cerebral Hemorrhage - complications | Hypertension | Stroke (Disease) | Complications and side effects | Candesartan | Research | Drug therapy | Health aspects | Studies | Stroke | Blood pressure | Clinical medicine | blood pressure | Hospitals | stroke | Mortality | myocardial infarction | composite materials | Medical and Health Sciences | MEDICINE | Medicin och hälsovetenskap | MEDICIN
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 04/2006, Volume 354, Issue 16, pp. 1685 - 1697
Persons with prehypertension (formerly, “borderline hypertension”) were randomly assigned in a blinded fashion to receive two years of candesartan or placebo,... 
UNITED-STATES | SPONTANEOUSLY HYPERTENSIVE RATS | MEDICINE, GENERAL & INTERNAL | NORMAL BLOOD-PRESSURE | METABOLIC CHARACTERISTICS | RISK-FACTORS | CONVERTING-ENZYME-INHIBITOR | CLINICAL-TRIAL | BORDERLINE HYPERTENSION | PREVENTION | PROGRESSION | Antihypertensive Agents - pharmacology | Angiotensin II Type 1 Receptor Blockers - adverse effects | Tetrazoles - pharmacology | Dyslipidemias - complications | Angiotensin II Type 1 Receptor Blockers - therapeutic use | Humans | Middle Aged | Biphenyl Compounds - adverse effects | Male | Angiotensin II Type 1 Receptor Blockers - pharmacology | Biphenyl Compounds - therapeutic use | Feasibility Studies | Incidence | Biphenyl Compounds - pharmacology | Hypertension - prevention & control | Adult | Female | Blood Pressure - drug effects | Hypertension - epidemiology | Benzimidazoles - adverse effects | Benzimidazoles - therapeutic use | Double-Blind Method | Obesity - complications | Logistic Models | Obesity - physiopathology | Antihypertensive Agents - therapeutic use | Antihypertensive Agents - adverse effects | Benzimidazoles - pharmacology | Tetrazoles - therapeutic use | Aged | Tetrazoles - adverse effects | Dyslipidemias - physiopathology | Hypertension | Dosage and administration | Research | Drug therapy | Candesartan | Automation | Blood pressure | Lifestyles
Journal Article
Hypertension, ISSN 0194-911X, 06/2012, Volume 59, Issue 6, pp. 1132 - 1138
Journal Article
Journal Article
Drugs, ISSN 0012-6667, 7/2016, Volume 76, Issue 10, pp. 1015 - 1022
Fimasartan is the ninth, and most recent, angiotensin II receptor antagonist approved as an antihypertensive agent. Fimasartan, a pyrimidin-4(3H)-one... 
Pharmacotherapy | Internal Medicine | Medicine & Public Health | Pharmacology/Toxicology | LOSARTAN | PHARMACOKINETICS | EFFICACY | ABSOLUTE BIOAVAILABILITY | ANTAGONIST FIMASARTAN | PARALLEL-GROUP | DOUBLE-BLIND | KOREAN PATIENTS | PHARMACOLOGY & PHARMACY | OPEN-LABEL | PHARMACODYNAMICS | TOXICOLOGY | Angiotensin II Type 2 Receptor Blockers - pharmacokinetics | Humans | Antihypertensive Agents - administration & dosage | Biphenyl Compounds - adverse effects | Hypertension - drug therapy | Biphenyl Compounds - therapeutic use | Dose-Response Relationship, Drug | Tetrazoles - administration & dosage | Observational Studies as Topic | Molecular Structure | Drug Evaluation, Preclinical | Drug Therapy, Combination | Biphenyl Compounds - pharmacokinetics | Pyrimidines - administration & dosage | Treatment Outcome | Angiotensin II Type 2 Receptor Blockers - adverse effects | Clinical Trials as Topic | Antihypertensive Agents - pharmacokinetics | Antihypertensive Agents - therapeutic use | Angiotensin II Type 2 Receptor Blockers - therapeutic use | Antihypertensive Agents - adverse effects | Hypertension - metabolism | Animals | Pyrimidines - therapeutic use | Biphenyl Compounds - administration & dosage | Pyrimidines - adverse effects | Pyrimidines - pharmacokinetics | Angiotensin II Type 2 Receptor Blockers - administration & dosage | Tetrazoles - therapeutic use | Tetrazoles - adverse effects | Tetrazoles - pharmacokinetics | Hypertension | Stroke (Disease) | Prevention | Care and treatment | Usage | Angiotensin II receptor blockers | Clinical trials | Dosage and administration | Index Medicus
Journal Article
JACC (Journal of the American College of Cardiology), ISSN 0735-1097, 2014, Volume 63, Issue 7, pp. 650 - 658
Objectives The study objective was to assess the association between angiotensin-converting enzyme inhibitor (ACEI)/angiotensin receptor blocker (ARB) use and... 
Cardiovascular | Internal Medicine | mortality | angiotensin-converting enzyme inhibitors | chronic kidney disease | angiotensin receptor blockers | SURVIVAL | SYSTEM INHIBITORS | CARDIAC & CARDIOVASCULAR SYSTEMS | PROPENSITY SCORE ANALYSIS | MYOCARDIAL-INFARCTION | ACE-INHIBITION | DIABETIC-NEPHROPATHY | CHRONIC RENAL-INSUFFICIENCY | HYPERTENSIVE PATIENTS | HEMODIALYSIS-PATIENTS | CONGESTIVE-HEART-FAILURE | Receptors, Angiotensin - metabolism | Follow-Up Studies | Angiotensin II Type 1 Receptor Blockers - therapeutic use | Humans | Middle Aged | Male | Renal Insufficiency, Chronic - drug therapy | Renal Insufficiency, Chronic - metabolism | Angiotensin-Converting Enzyme Inhibitors - therapeutic use | Aged, 80 and over | Renal Insufficiency, Chronic - mortality | Female | Aged | Cohort Studies | Hypertension | Sects | Chronic kidney failure | Patient outcomes | Mortality | Angiotensin | ACE inhibitors | Medical research | Analysis | Medicine, Experimental | Angiotensin-converting enzyme inhibitors | Laboratories | Cardiovascular disease | Subgroups | Confidence intervals | Enzyme inhibitors | Motivation | Peptidyl-dipeptidase A | Heart failure | Urine | Enzymes | Statistical analysis | Kidneys | Comorbidity | Diabetes mellitus | Calendars | Regression analysis | Patients | Inhibitors | Statistical models | Converting | Pharmacy | Coronary vessels | Diabetes | Kidney diseases | Potassium
Journal Article
The American journal of medicine, ISSN 0002-9343, 03/2019
Ranolazine is an anti-angina agent with many metabolites creating the potential for off-target effects. The U.S. Food and Drug Administration (FDA) reviews... 
Journal Article